Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as DTG Tablet, DTG
DTG/3TC · 1 trial · 2 indications
Participants with HIV-1 RNA \>= 50 c/mL were evaluated. Virologic outcome was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the Week 48 Window. The analysis was done using the modified Snapshot algorithm.
| Arm | Type | Description |
|---|---|---|
| Participants Receiving Dolutegravir/Lamivudine (DTG/3TC) Fixed-dose combination (FDC) | EXPERIMENTAL | Participants living with HIV switched from Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) on Day 1 and received once daily dose of DTG/3TC FDC for 96 weeks. At Week 96, all participants switched to locally available DTG/3TC FDC or local standard of care (SOC) Antiretroviral Therapy (ART). |
| Name | Type | Description |
|---|---|---|
| DTG/3TC | DRUG | DTG/3TC FDC was administered once daily. |
Inclusion Criteria: * Participants living with HIV-1 and had documented plasma HIV-1 RNA \<50 c/mL within 3 months prior to Screening. * Participants had been on uninterrupted ART for ≥1 year (except for brief periods \[less than 30 days\] where all ART had been stopped due to tolerability and/or s...
DTG is an investigational small molecule in Phase 3 clinical development for the treatment of HIV infections, including human immunodeficiency virus type 1. It is being studied in adults and adolescents as part of combination antiretroviral regimens, including switch studies for virologically suppressed patients and as initial therapy in treatment-naive individuals.
DTG is a small molecule antiretroviral agent. Its specific molecular target is not disclosed in the available clinical trial information. The drug is being evaluated in Phase 3 studies for HIV treatment, often in combination with other antiretrovirals such as rilpivirine or lamivudine.
DTG is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting Phase 3 clinical trials to evaluate the drug's efficacy and safety in treating HIV infections across multiple countries.
DTG is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trials are completed, with no active trials currently ongoing, and the drug is being studied for the treatment of HIV infections.
DTG has been studied in several Phase 3 clinical trials, including NCT02429791 (SWORD-1), a switch study to dolutegravir plus rilpivirine in virologically suppressed adults; NCT03446573 (TANGO), a switch study to dolutegravir plus lamivudine; NCT03682848, a study in treatment-naive HIV-1 infected adolescents; and NCT05917509, a study comparing oral once-daily and long-acting injectable regimens in treatment-naive adults.
Yes, DTG is also known as DTG Tablet. The drug is referred to by both names in clinical research contexts. It is being developed as an oral small molecule for the treatment of HIV infections and is currently in Phase 3 clinical trials.